IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-19288-6.html
   My bibliography  Save this article

Immune modulatory effects of oncogenic KRAS in cancer

Author

Listed:
  • Shaima’a Hamarsheh

    (Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg)

  • Olaf Groß

    (Institute of Neuropathology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg
    Centre for Biological Signalling Studies (BIOSS) and Centre for Integrative Biological Signalling Studies (CIBSS), University of Freiburg)

  • Tilman Brummer

    (Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg
    German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ)
    Comprehensive Cancer Centre Freiburg (CCCF), University of Freiburg)

  • Robert Zeiser

    (Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
    Centre for Biological Signalling Studies (BIOSS) and Centre for Integrative Biological Signalling Studies (CIBSS), University of Freiburg
    German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ)
    Comprehensive Cancer Centre Freiburg (CCCF), University of Freiburg)

Abstract

Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream signalling is a main driver of carcinogenesis, there is increasing evidence that it also mediates autocrine effects and crosstalk with the tumour microenvironment (TME). Here, we discuss recent reports connecting KRAS mutations with tumour-promoting inflammation and immune modulation caused by KRAS that leads to immune escape in the TME. We discuss the preclinical work on KRAS-induced inflammation and immune modulation in the context of currently ongoing clinical trials targeting cancer entities that carry KRAS mutations and strategies to overcome the oncogene-induced effects on the immune system.

Suggested Citation

  • Shaima’a Hamarsheh & Olaf Groß & Tilman Brummer & Robert Zeiser, 2020. "Immune modulatory effects of oncogenic KRAS in cancer," Nature Communications, Nature, vol. 11(1), pages 1-11, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19288-6
    DOI: 10.1038/s41467-020-19288-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-19288-6
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-19288-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Qiming Zhou & Yao Peng & Fenfen Ji & Huarong Chen & Wei Kang & Lam-Shing Chan & Hongyan Gou & Yufeng Lin & Pingmei Huang & Danyu Chen & Qinyao Wei & Hao Su & Cong Liang & Xiang Zhang & Jun Yu & Chi Ch, 2023. "Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    2. Manuel Rodrigues & Giulia Vanoni & Pierre Loap & Coraline Dubot & Eleonora Timperi & Mathieu Minsat & Louis Bazire & Catherine Durdux & Virginie Fourchotte & Enora Laas & Nicolas Pouget & Zahra Castel, 2023. "Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    3. Chi Zhou & Wenxin Li & Zhenxing Liang & Xianrui Wu & Sijing Cheng & Jianhong Peng & Kaixuan Zeng & Weihao Li & Ping Lan & Xin Yang & Li Xiong & Ziwei Zeng & Xiaobin Zheng & Liang Huang & Wenhua Fan & , 2024. "Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death," Nature Communications, Nature, vol. 15(1), pages 1-21, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19288-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.